Human study for investigating the effects of chronic intake of a combined extract of grape and omija on body fat level and related metabolism in obese adults

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0001832

Enrollment

Registered

2016-03-02

Start date

2016-03-09

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Consumption of placebo or combined extract of grape and omija, once a day for 12 weeks (ample 40ml)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Subject who voluntarily agree to participate and signs informed consent form 2) 20 years= Age <65 years (= 64years) 3) 25kg/m2= BMI =30kg/m2

Exclusion criteria

Exclusion criteria: 1) Administration of medicine that affect body weight : appetite suppressants/accelerators, diuretic, beta-blocker, contraceptive, steroid drug, TCA drug, postmenopausal hormone medicine, laxatives, antidepressant et al. 2) Participation in commercial obesity program or experience of calorie-restricted theraphy within three months before the first visit 3) Subject who has consumed of dietary supplements or oritental medicine within one month before the first visit 4) Subject with body weight change more than 3kg within three months before the first visit 5) Subject with surgical experience (esophagogastroplasty, enterectomy, et al.) for weight loss 6) Subject with experience of severe depression (hospital treatment or attempt case) 7) Subject with experience of epilepsy or eating disorder 8) Subject with following disease: - Hypertension - Diabetes(use of hypoglycemic agent) , fasting blood glucose= 180mg/dl - Liver dysfunction (ALT or AST > 80 U/L) - Renal dysfunction (Creatinine > the upper limit of normal level x 1.5) - Hyperthyroidism or hypothyroidism - Malignant tumor, heart diesase, lung diseases, asthma, nerve/mental disorder, stomach and intestines disease, hepatitis, Cushing's disease, tuberculosis 9)Subjects with hypersensitivity to test materials 10) Participation in other human study within one month before the first visit 11) Pregnant or lactating women 12) Subjects with difficult to use smartphone 13) Any condition that the principal investigator believes may put the subjects at undue risk

Design outcomes

Primary

Measure	Time frame
Maker of fat level	—

Secondary

Measure	Time frame
Lipid level, etc.	—

Countries

Korea, Republic of

Contacts

Public Contactkyung kim

The Catholic University of Korea, Seoul St. Mary's Hospital

cmckskim@gmail.com+82-2-2258-6284

Outcome results